Victoria's Secret & Co vs GeneDx Holdings Corp — how do they compare? Victoria's Secret & Co trades at $87.1 (market cap $6.95B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Victoria's Secret & Co is far larger — about 3.9× GeneDx Holdings Corp's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VSXY | WGS | |
|---|---|---|
Market Cap | $6.95B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $88.50 | $167.51 |
52-Week Low | $18.72 | $34.51 |
Enterprise Value | $9.59B | $1.80B |
Signals from Pluang's Aura AI — not financial advice
Victoria's Secret (VSXY) trades at $87.09, up 6.92% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows improving fundamentals with revenue stabilizing at $6.23B in 2025 and net income recovering to $165M. Analyst consensus is bullish with a $88.56 price target, and institutional interest is growing, evidenced by Bessemer Group's increased stake in Q1 2026.
The outlook remains positive driven by international expansion, particularly in China, and product innovation. Risks include competitive pressures in retail and margin volatility. With no sell ratings from analysts and strong shareholder support for management, VSXY presents a growth opportunity, though investors should monitor execution on guidance and macroeconomic impacts on consumer spending.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Trailing returns across standard periods
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →